Catalog No.
RHE22301
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, IHC: 1:200-1:1000
Target
BRCA1, Breast cancer type 1 susceptibility protein, RING-type E3 ubiquitin transferase BRCA1, RING finger protein 53, RNF53
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P38398
Applications
ELISA, IHC
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3K14
Genomic profiles of pathogenic and moderate-penetrance germline variants associated with risk of early-onset lung adenocarcinoma., PMID:40516820
Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers., PMID:40507303
New Treatment Approaches for Triple-Negative Breast Cancer., PMID:40460322
Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer., PMID:40446758
Ultrasensitive Analysis of BRCA-1 Based on Gold Nanoparticles and Molybdenum Disulfide Electrochemical Immunosensor with Enhanced Signal Amplification., PMID:40422069
Unraveling SET: Exploring ovarian high-grade serous carcinoma and its BRCA1/2 immunoexpression., PMID:40405589
Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma., PMID:40377969
Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma., PMID:40362535
The role of tungsten in modulating DNA double-strand break repair and class switch recombination., PMID:40360058
BAP1-mediated ubiquitination inhibition and CAS6/AXL signaling activation in bladder cancer progression., PMID:40330545
Advances in Targeted Therapy for Metastatic Prostate Cancer., PMID:40299225
Genetic determinants of proteomic aging., PMID:40287427
PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer., PMID:40273724
Oncogenic activation of SMYD3-SHCBP1 promotes breast cancer development and is coupled with resistance to immune therapy., PMID:40157910
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance., PMID:40141188
A Critical Role of Intracellular PD-L1 in Promoting Ovarian Cancer Progression., PMID:39996786
Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report., PMID:39969335
Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence., PMID:39914385
Opportunities for predictive proteogenomic biomarkers of drug treatment sensitivity in epithelial ovarian cancer., PMID:39839766
Evaluation of Breast Cancer Gene Type 1 (BRCA1) Protein Levels in Cancer Tissue Using Surface-Enhanced Raman Spectroscopy., PMID:39636020
Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms., PMID:39572842
[Use of sacituzumab govitecan in frail patients with skin disease.]., PMID:39550676
Proteomic biomarkers profiling in Pakistani pancreatic ductal adenocarcinoma population: a retrospective cohort study., PMID:39508439
BRCA1 Protein Expression in Epithelial Ovarian Cancer and Associated Clinicopathological Factors in Uganda., PMID:39502381
[The evolution of a luminal breast cancer to a triple-negative and its impact on disease control with sacituzumab govitecan.]., PMID:39446008
Neutralization of the autophagy-repressive tissue hormone DBI/ACBP (diazepam binding inhibitor, acyl-CoA binding protein) enhances anticancer immunosurveillance., PMID:39419485
A novel molecular target, superoxide dismutase 1, in ALK inhibitor-resistant lung cancer cells, detected through proteomic analysis., PMID:39313177
Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab., PMID:39269823
PARP inhibitor resistant BRCA-mutated advanced breast cancer: current landscape and emerging treatments., PMID:39246166
Acyl-coenzyme a binding protein (ACBP) - a risk factor for cancer diagnosis and an inhibitor of immunosurveillance., PMID:39242519
From cortisol-producing adrenal adenoma to atrial myxoma, through nivolumab-induced hypophysitis: a complicated case report of Carney Complex., PMID:39217593
Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study., PMID:39116683
Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective., PMID:39102671
Type I or Type II Endometrial Carcinoma? Role of BRCA1 Immunohistochemistry., PMID:39068563
Germline BARD1 variants predispose to mesothelioma by impairing DNA repair and calcium signaling., PMID:38990952
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers., PMID:38971950
[Long-term response to second-line treatment with sacituzumab govitecan in a patient affected by brain disease and early relpased TNBC.]., PMID:38853740
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy., PMID:38704093
Should all advanced BRCA-mutated patients in response to first-line platinum-based chemotherapy receive PARPi + bevacizumab as maintenance therapy?, PMID:38663167
Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study., PMID:38658024
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer., PMID:38640773
Characterization of immortalized ovarian epithelial cells with BRCA1/2 mutation., PMID:38615309
Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases., PMID:38600429
Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA-Like Genomic Aberrations., PMID:38592722
Targeting PARG induces tumor cell growth inhibition and antitumor immune response by reducing phosphorylated STAT3 in ovarian cancer., PMID:38580335
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy., PMID:38551024
PARP Inhibitors for Breast Cancer Treatment: A Review., PMID:38512229
Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair., PMID:38383600
The DNA helicase FANCJ (BRIP1) functions in double strand break repair processing, but not crossover formation during prophase I of meiosis in male mice., PMID:38377115
HER2-Low Expression in Male Breast Cancer: Results from a Multicenter Series in Italy., PMID:38339299
For research use only. Not for human or drug use.
